OTC: VYCO

NovaVision

NovaVision
provides non-invasive, computer-based rehabilitation therapies targeted at people who have impaired vision as a result of stroke or other
brain injury.

Strategy

The
Company is continuing to execute on a plan to achieve revenue growth. The strategy for Vycor Medical includes: increasing market penetration
in the US; increasing international growth in territories where we are not represented or under-represented; continued new product development
in response to market demands and demonstrating applicability in a broader range of pathologies; and adding products complementary to
VBAS where the Company is able to leverage its existing distribution network.

Given
NovaVision’s resources, and the large size and diversity of its end markets, we believe that the most efficient way to tackle the
distribution of its patient and professional products is by partnering with entities that have either direct access to the end users
or the technological capability to leverage the NovaVision therapy platform, particularly in digital health and into non-medical areas.
Management is also open to a broad range of alternatives for NovaVision as a whole, which could comprise distribution and marketing partnerships,
licensing, merger or sale.

In
August 2024 the Company engaged the services of Maxim Group LLC to assist in its strategy to accelerate the growth of the Company through
strategic acquisitions and partnerships.

3

3.
Other Matters

Product
Liability Insurance

We
presently have Product Liability insurance for Vycor Medical and Professional Liability insurance for NovaVision.

Government
Regulations

We
are committed to an integrated total quality management system and to obtain and maintain regulatory certification for our products in
the markets in which we operate.

Vycor
Medical has the following regulatory certification/licensing:

●
ISO
13485:2016

●
MDSAP
(Medical Device Single Audit Program)

●
Fully
Quality Assurance System Directive 93/42/EEC for Medical Devices, Annex II (3)

●
EC
Design-Examination Certificate Directive 93/42/EEC for Medical Devices, Annex II (4)

Vycor
Medical’s VBAS family of devices have been classified as Class II products by the FDA and cleared for marketing through the 510(k)
process. NovaVision’s VRT product has been cleared as a Class U product through the 510(k) while its NeuroEyeCoach is registered
as an exempt Class 1 device.

Vycor
Medical has CE marking approval for distribution of its VBAS products in Europe as a Class III device under (EU) MDR and has a Health
Canada Medical Device License (MDL) for distribution in Canada as a Class II device. VBAS also has regulatory approvals in a number of
other international markets. NovaVison’s VRT and NeuroEyeCoach have CE mark registrations as Class I devices in Europe.

Employees

We
currently have 7 employees.

Website.

The
Company operates websites at www.vycormedical.com, www.vycorvbas.com, and www.novavision.com. NovaVision’s German partner maintains
the www.novavision.de website.